News
China Medical System Announced Collaboration And License Agreement With Incyte For Selective Oral Smallmolecule JAK1 Inhibitor Povorcitinib
1 Apr 24
News
RBC Capital Reiterates Sector Perform on Incyte, Maintains $65 Price Target
25 Mar 24
News, Price Target, Reiteration, Analyst Ratings
B of A Securities Maintains Neutral on Incyte, Lowers Price Target to $67
13 Mar 24
News, Price Target, Analyst Ratings
Stifel Reiterates Hold on Incyte, Maintains $68 Price Target
12 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
12 Mar 24
Analyst Ratings
RBC Capital Reiterates Sector Perform on Incyte, Maintains $65 Price Target
12 Mar 24
News, Price Target, Reiteration, Analyst Ratings
New Data From Incyte's Dermatology Portfolio To Be Presented At The 2024 American Academy Of Dermatology Annual Meeting
4 Mar 24
Biotech, News, Events, General
Jefferies Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $81
23 Feb 24
News, Price Target, Initiation, Analyst Ratings
JMP Securities Downgrades Incyte to Market Perform
14 Feb 24
News, Downgrades, Analyst Ratings
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $65
14 Feb 24
News, Price Target, Analyst Ratings
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
14 Feb 24
Analyst Ratings
Incyte Expects 2024 Jakafi Net Product Revenues Of $2.69B-$2.75B
13 Feb 24
News, Guidance
Incyte Q4 Adj EPS $1.06 Misses $1.16 Estimate, Sales $1.01B Beat $1.00B Estimate
13 Feb 24
Earnings, News
Earnings Scheduled For February 13, 2024
13 Feb 24
Earnings
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
6 Feb 24
Biotech, Large Cap, M&A, News, Health Care, Movers, Trading Ideas, General
Incyte Enters Asset Purchase Agreement With Morphosys; Gains Exclusive Global Development And Commercialization Rights To Tafasitamab (Monjuvi)
5 Feb 24
News
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
5 Feb 24
Biotech, News, Movers & Shakers
Press releases
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29 Mar 24
Press Releases
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
10 Mar 24
Press Releases
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
10 Mar 24
Press Releases
New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
4 Mar 24
Press Releases
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI
29 Feb 24
Press Releases
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
29 Feb 24
Health Care, Press Releases, General
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
27 Feb 24
Press Releases
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
13 Feb 24
Press Releases
Pancreatic Cancer Treatments Poised for Major Advances in 2024
7 Feb 24
Small Cap, Opinion, Press Releases
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
5 Feb 24
Press Releases